An intensive 2-day in person meeting that delves into the latest in vaccine research, platform technologies, development and manufacturing & a meeting place for experts working within cutting-edge vaccine research [….]
Vector BioMed Launches in Maryland with Gene Therapy Industry Veteran at Helm to Address the Vector Supply Bottleneck with End-to-End Solutions Platform
Biomanufacturing Company Vector BioMed Launches with Mission to Provide Access to High-Quality Lentiviral Vectors and Address the Vector Supply Bottleneck
NEWS PROVIDED BY
Vector BioMed
Jan 31, 2023, 07:30 ET
SHARE THIS ARTICLE
First Round Funding Led by Viking Global Investors and Casdin Capital
Boro Dropulić, Ph.D., MBA, named Chief Executive Officer of Vector BioMed
GAITHERSBURG, Md., Jan. 31, 2023 /PRNewswire/ — Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, today announced its launch and first financing round led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
In contrast to traditional contract development and manufacturing organizations (CDMOs), Vector BioMed is a solution provider that will provide partners with the capabilities to take their lentiviral vector-based medicinal concepts into the clinic and accelerate their path to commercialization. Vector BioMed will help address the industry’s current vector supply bottleneck by providing lentiviral vectors at scale, while also offering turnkey solutions for vector design and optimization, pre-clinical manufacturing, GMP manufacturing, and other support services.
In conjunction with the funding and launch, co-founder Boro Dropulić, Ph.D., MBA has…
Vigene Biosciences Plans Major Expansion in Maryland, Adding up to 245 Jobs
Vigene, a gene therapy development company, said it intends to lease a 52,000 square-foot manufacturing space at 14200 Shady Grove Road that will nearly double the company’s existing manufacturing footprint. The new space is in addition to its existing headquarters, R&D, and manufacturing locations that opened in Rockville last year. The additional space from the new facility will allow the company to expand its current headcount of 125 by the addition of 245 more employees.
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability June 18, 2020 Company acquires property adjacent to its Canton, Massachusetts live viral [….]